Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101, a topical cream targeting alpha adrenergic receptors on small blood vessels that has completed Phase II testing to treat erythema in patients with rosacea. Allergan would not provide a timeline for when it expects Phase III testing to begin. ...